Cell Culture Market Estimated to Cross USD 60.27 BN by 2030

The global Cell Culture market size was estimated at USD 21.05 billion in 2021 and is expected to surpass around USD 60.27 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 11.9% during the forecast period 2022 to 2030.

Request Free Sample of This Report@ https://www.novaoneadvisor.com/report/sample/6787

Key Takeaways:

• By Application, the U.K. Cell Culture market was valued at USD 1.4 Billion in 2021 and expected to witness growth at a CAGR of 14.9% from 2022 to 2030.
• By consumable, the media segment accounted for the largest revenue share of over 50.0% in 2021 due to the availability of a variety of serum- and animal component-free and customized media alternatives, which has increased the market penetration for media products
• Based on product, culture systems held the largest revenue share of over 25.0% in 2021. This can be attributed to the technological advancements in automated systems for research & development applications
• The biopharmaceuticals application segment dominated the market in 2021 with a revenue share of over 25.0% due to the involvement of mammalian lines, such as the Chinese hamster ovary, in the manufacturing of biopharmaceuticals and the rising demand for non-conventional drugs
• North America held the largest revenue share in 2021 due to high research and development investments, presence of a well-established scientific infrastructure, significant demand for animal component-free media, and other factors
• The Asia Pacific region is estimated to grow at the fastest rate over the forecast period due to the growing healthcare expenditure, rising awareness regarding regenerative therapies, and a large potential for clinical research applications

Advancements in 3D culture technologies and their increasing adoption for biopharmaceutical production, drug discovery, and tissue engineering applications are anticipated to boost the industry growth. Recent developments in gene expression technologies have enabled the production of novel vaccines and biopharmaceuticals, thereby increasing the research & development applications of cell culture techniques. Moreover, a rise in the number of cancer research projects and broadening scope of applications for gene therapies are expected to drive the market.

The COVID-19 pandemic has boosted the demand for cell culture products due to the significant role played by cell culture technologies in the discovery of novel diagnostic and therapeutic options for the disease. For instance, research applications of cell lines such as high-throughput COVID-19 drug screening for identification of potential drug candidates and investigations aimed at understanding the mechanism of viral entry into the host cells are expected to positively affect the market growth. Furthermore, culturing techniques offer essential tools for the production of viral particles for vaccine development, thereby broadening the growth prospects in this domain.

Demand for cytological offerings provided by contract research organizations is expected to rise due to the cost-intensiveness and expertise required for setting up cell culture infrastructure. Moreover, regenerative therapy research has attained tremendous growth in recent years due to the large amounts of investments funneled into this domain. As cell culture techniques constitute an essential step in such research applications, the market is expected to witness significant growth in the near future.

Key players involved in the market are undertaking initiatives to extend their product portfolios and strengthen their market position. For instance, in January 2022, Cytiva (Danaher Corporation) collaborated with Nucleus Biologics for the development of custom culture media for cell and gene therapies. Furthermore, expansion of the existing service offerings is being undertaken by emerging players to enhance their market presence. For instance, in February 2022, KromaTiD expanded its service offerings with the launch of cell and blood culture isolation, processing, and quality control services.

In addition, continuous advancements in regenerative medicines and high unmet medical needs in emerging markets are expected to drive the adoption of cell culture technologies. Government initiatives in this domain are further contributing to the industry growth. For instance, in January 2022, India’s Union Health Ministry amended the New Drugs & Clinical Trials Rules for the addition of cell-derived or stem cell-derived products into the scope of new drugs. This provided a robust regulatory structure for governing the production of cell-derived products in the country and is expected to positively affect the industry growth.

Furthermore, growth in the prevalence of chronic diseases, such as cancer and cardiovascular diseases, has led to an increased focus on cytological studies, leading to rising demand for culture systems and media products. For instance, according to the WHO, cardiovascular diseases lead to over 17.9 million deaths each year. Such a high number of fatalities is anticipated to attract further research attention in this domain and increase the growth opportunities for cell culture offerings.

Report Scope of the Cell Culture Market

 Ask here for more customization study@ https://www.novaoneadvisor.com/report/customization/6787

Consumable Insights

Media held the largest revenue share of over 50.0% in 2021 due to high demand for media products for research and development applications. The availability of a variety of serum- and animal component-free and customized media alternatives has increased the market penetration for media products. Furthermore, specialized media for stem cell applications is being increasingly commercialized, which is expected to boost the growth of the segment. For instance, companies such as Thermo Fisher Scientific, Inc. and Sartorius AG offer media products optimized for stem cell culturing.

The reagents segment is expected to register the fastest CAGR over the forecast period due to the increasing significance of albumin for carrying serum-derived substances that support mammalian cultures. Other reagents such as antibiotics and amino acids are being increasingly used for applications in primary cultures to ensure the maintenance of a sterile and nutrient-rich environment in the culture systems. These factors are expected to significantly boost the segment growth. 

Product Insights

Culture systems dominated the market and accounted for over 25.0% share in 2021. The segment is also expected to register the fastest CAGR over the forecast period due to the development of technologically advanced and automated culturing systems. For instance, in March 2022, CELLINK launched its BIO CELLX bio-dispensing platform for the automation of 3D cell-based assays for drug discovery and cancer research. Such product launches are likely to broaden the growth prospects for the segment.

Centrifuges are anticipated to witness significant growth over the forecast period as benchtop centrifuges are gaining efficiency in operations and they offer reliability for everyday laboratory use. Furthermore, bioprocessing centrifuges are commercially available for high-quality, rapid, and high-yield cell separation, which can increase the adoption of the technique. With the growing need for centrifuges for the production of gene therapies, antibodies, and vaccines, the demand for the product is expected to grow in the near future.

Application Insights

The biopharmaceuticals segment held the largest revenue share of over 25.0% in 2021. Due to the involvement of mammalian cell lines, such as the Chinese hamster ovary, in the manufacturing of biopharmaceuticals and the rising demand for non-conventional drugs, biopharmaceutical applications of cell culture techniques are expected to witness growth. In addition, the development of several grafting techniques and personalized treatment options in recent years has expanded the growth prospects in the biopharmaceutical domain.

Vaccine production is projected to expand at a lucrative CAGR over the forecast period due to the increasing importance of culturing techniques for the production of viral vaccines grown using Madin-Darby Canine Kidney, pMK, Vero, or human lines such as HEK 293 and MRC 5. With accelerated vaccine approval processes and large investments in vaccine manufacturing fueled by the COVID-19 pandemic, vaccine production applications of the technique are likely to positively affect the industry growth.

Regional Insights

North America held the largest revenue share of over 40.0% in 2021 due to high research and development investments, the presence of a well-established scientific infrastructure, significant demand for animal component-free media, and other factors. 

Furthermore, ongoing research and expansion of the biopharmaceutical sector in the U.S. are expected to boost the industry growth in the region. The presence of key players such as Bio-Rad Laboratories, Inc.; Thermo Fisher Scientific, Inc.; and Becton, Dickinson and Company can significantly drive the market.

The Asia Pacific region is projected to expand at the fastest CAGR over the forecast period due to the growing healthcare expenditure, rising awareness regarding cell and gene therapies, and a large potential for clinical research applications. Furthermore, rapid adoption of scientific technologies and emerging therapeutics, such as regenerative medicines and cancer immunotherapies, is likely to strengthen the industry growth in the near future.

Some of the prominent players in the Cell Culture Market include:

• Bio-Rad Laboratories, Inc.
• Thermo Fisher Scientific, Inc.
• Becton, Dickinson and Company
• Merck KGaA
• Sartorius AG
• VWR International, LLC
• Eppendorf SE
• PromoCell GmbH
• Bio-Techne Corporation
• BioSpherix, Ltd.

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Cell Culture market

• Consumable
  • Media
    • Minimum Essential Media (MEM)
    • RPMI 1640 Media
    • DMEM/F-12 Media
    • F-10 Serum Free Media
    • BME Media
    • Insect Media
    • Other Media
  • Sera
    • Fetal Bovine Serum
    • Other AnimalSerum
  • Reagents
    • Albumin
    • Other
• Product
  • Culture Systems
  • Incubators
  • Centrifuges
  • Cryostorage Equipment
  • Biosafety Equipment
  • Pipetting Instruments
• Application
  • Biopharmaceuticals
  • Tissue Culture & Engineering
  • Vaccine Production
  • Drug Development
  • Gene Therapy
  • Toxicity Testing
  • Cancer Research
  • Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Full Report is Ready | For Purchase Inquiry@ https://www.novaoneadvisor.com/report/checkout/6787

You can place an order or ask any questions, please feel free to sales@novaoneadvisor.com| +1 9197 992 333

Blog: https://www.novaoneadvisor.com/

Blog: https://www.visionresearchreports.com/

Blog: https://qyresearchmedical.com/